Search results
Results from the WOW.Com Content Network
An article published by the journal Nature on 6 July 2021 cited data released by the United Arab Emirates on some 81,000 individuals who had received Sputnik V, according to which the vaccine demonstrated an efficacy of 97.8% in preventing symptomatic COVID-19, and 100% efficacy in preventing severe complications.
Retrospective cohort study of the effectiveness of two Russian vaccines against the SARS-CoV-2 Delta variant in Moscow (June–July 2021) proved that EpiVacCorona, unlike Sputnik V, is an ineffective vaccine and therefore cannot protect against COVID-19.
A vaccine is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval. [6] As of September 2021, no study on Sputnik Light reported confidence intervals, so it is not possible to know the accuracy of the estimates. Effectiveness is generally expected to slowly decrease over time. [7]
English: Sputnik V efficacy for different conditions. Data from: Logunov D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Vaccine Initial effectiveness by severity of COVID-19 Study location Refs Asymptomatic Symptomatic Hospitalization Death Oxford–AstraZeneca
Relevant to how vaccines can end the pandemic by preventing asymptomatic infection, they have also indicated possibly reduced antibody neutralization against Beta with most of the widely distributed vaccines (Oxford–AstraZeneca, Sputnik V, Janssen, Pfizer–BioNTech, Moderna, Novavax; minimal to substantial reduction) except CoronaVac and ...
South Korea's Korus Pharm has formed a consortium to produce Russia's Sputnik V COVID-19 vaccine. the consortium will produce 500 million doses of the vaccine. [26] However, The Sputnik V doses manufactured in South Korea are not for domestic use. [27] The vaccine is to be exported to Russia and UAE. [28] Novavax will license out its NVX ...
On 11 August 2020, President Putin said in a meeting that the Sputnik V vaccine (registered as Gam-COVID-Vac) developed by the Gamaleya Research Institute of Epidemiology and Microbiology was the first vaccine against the coronavirus to be registered.